- Phase 3 ATTAIN‑1 (n=3,127; 195 aged ≥65, no T2D) and ATTAIN‑2 (n=1,613; 418 aged ≥65, with T2D) were 72‑week randomized, double‑blind trials of orforglipron 5.5, 9 and 17.2 mg versus placebo.
- In adults ≥65, mean weight change at 72 weeks in ATTAIN‑1 was −7.9%, −11.3% and −13.0% and in ATTAIN‑2 was −7.5%, −8.3% and −12.2% for 5.5, 9 and 17.2 mg versus ~−1.6%/−2.3% placebo.
- Gastrointestinal adverse events were the most frequent side effects, and pooled serious adverse events in participants ≥65 ranged ~9.9–13.0% across doses versus 11.4% with placebo.
- Starting July 1, 2026, Medicare beneficiaries can access Foundayo through the Medicare GLP‑1 Bridge program with a $50 monthly copay.
Key findings
Post‑hoc analysis of Phase 3 ATTAIN‑1/2 showed orforglipron (Foundayo) produced significant mean weight reductions at 72 weeks in adults ≥65: ATTAIN‑1 (no T2D) −7.9%, −11.3%, −13.0% for 5.5, 9 and 17.2 mg versus −1.6% placebo; ATTAIN‑2 (with T2D) −7.5%, −8.3%, −12.2% versus −2.3% placebo, with results broadly consistent versus participants <65.
Trials and analysis
ATTAIN‑1 (n=3,127; 195 aged ≥65) and ATTAIN‑2 (n=1,613; 418 aged ≥65) were 72‑week randomized, double‑blind, placebo‑controlled trials testing once‑daily orforglipron 5.5, 9 and 17.2 mg; this report is a post‑hoc subgroup analysis by age with percent change in body weight at Week 72 as the primary endpoint.
Safety
Gastrointestinal adverse events (nausea, constipation, diarrhea, vomiting) were most frequent; pooled serious adverse events in participants ≥65 ranged roughly 9.9–13.0% across doses versus 11.4% with placebo; overall safety was reported as generally consistent across age groups.
Limitations
Analysis was post‑hoc and exploratory, subgroup sizes (≥65) were smaller than <65, comparisons by age were not pre‑specified, and findings are hypothesis‑generating pending prospective confirmation.
Access
Beginning July 1, 2026, Medicare beneficiaries can access Foundayo through the Medicare GLP‑1 Bridge program with a $50 monthly copay.
